NeurologyLive® Friday 5 — June 17, 2022

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: The Aducanumab Saga and the Future of Antiamyloid Monoclonal Antibodies

David S. Knopman, MD, writes on the journey of aducanumab (Aduhelm; Biogen) from development to the FDA—a tortured one. But, its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.

2: Mind Moments™ Episode 66: 2022 SLEEP Annual Meeting Highlights

Mind Moments™, a podcast from NeurologyLive^®, brings you exclusive interviews with experts in the treatment and management of sleep disorders as a recap of the 2022 SLEEP Annual Meeting.

3: NeuroVoices: Tanuja Chitnis, MD, on Targeting Anti-CD3, Other Biomarkers in Progressive Multiple Sclerosis

The associate neurologist at Brigham and Women’s Hospital discussed the potential of a nasal anti-CD3 monoclonal antibody, foralumab, and its impact on biomarkers specific to patients with progressive multiple sclerosis.

4: Exposing Young Professionals to Multiple Sclerosis Care, Interdisciplinary Teams: Stephanie Teixiera-Poit, PhD

The associate professor at the North Carolina Agricultural and Technical State University discussed a newfound initiative that helps encourage more professionals in multiple sclerosis and across the breadth of neurology.

5: New Treatments in Migraine: An In-Depth Review

Jessica Ailani, MD, and Arathi Nandyala, MD, write that although new treatments and innovations are a sign of growth in migraine care, it is important to realize that growth comes with a certain amount of pain. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma.

—————————————————